

CONTENTS

Programme Committee	1
List of Participants	3
Foreword	7
Introduction	9

1. OVERVIEW

Malignancies induced by drug therapy: a review	
I. Penn	13
Carcinogenicity of anticancer drugs and especially alkylating agents	
D. Schmähl	29
Clinical use of chemotherapeutic agents	
J.P. Obrecht & R. Obrist	37

2. MACROMOLECULAR INTERACTIONS

Reactions of nitrogen mustards with DNA	
K. Hemminki & S. Kallama	55
Nature and biological significance of DNA modification by the haloethylnitrosoureas	
D.B. Ludlum	71
Interactions of the antitumour drug cisplatin with DNA <i>in vitro</i> and <i>in vivo</i>	
A.M.J. Fichtinger-Schepman, J. Reedijk, A.T. van Oosterom, P.H.M. Lohman & F. Berends	83
Unique properties of cisplatin in reactions with nucleophiles	
A. Försti & K. Hemminki	101
Carcinogenicity of cytostatic triazenes	
G.F. Kolar	111
Quantification of methoxsalen-DNA adducts with specific antibodies	
R.M. Santella, F.P. Gasparro & R.L. Edelson	127

3. BIOLOGICAL EFFECTS

Antitumour alkylating agents: cytotoxic action and organ toxicity T.A. Connors	143
Chromosome damage and second malignancy in patients treated with melphalan B. Lambert, K. Holmberg & N. Einhorn	147
Carcinogenicity of alkylating cytostatic drugs in animals M.R. Berger	161
New experimental approaches to reducing carcinogenicity in animals by modifying regimens M. Habs & D. Schmähl	177

4. EPIDEMIOLOGICAL INVESTIGATIONS

Epidemiological studies of anticancer drug carcinogenicity J.M. Kaldor, N.E. Day & S. Shiboski	189
A case-control study of leukaemia as a second primary malignancy following ovarian and breast neoplasms W.H. Mehnert, J.F. Haas, J.M. Kaldor, N.E. Day, B. Kittelmann, W. Staneczek & M. Möhner	203
Carcinogenicity of nitrosoureas in humans R. Preussmann	223
Second primary tumours among survivors of childhood cancer treated with anticancer drugs M.M. Hawkins	231
An approach to monitoring mutation rates using restriction fragment lengths M.H. Skolnick	253

5. PROSPECTS FOR THE FUTURE

Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics N. Brock & J. Pohl	269
Drug design: nitrosoureas G. Eisenbrand, M.R. Berger, W.J. Zeller, H. Fiebig, N. Müller, J. Schreiber, W. Stahl & W. Sterzel	281

Design of metallocenic drugs	
J. Engel, W. Schumacher & H. Schönenberger	295
Oncogenes and other new targets for cancer chemotherapy	
H. Busch	309
Carcinogenicity of alkylating cytostatic drugs: conclusions and directions for future research	
J. Kaldor & D. Schmähl	321
Index of authors	327
Subject index	331

H.-P. Baumann, German Cancer Research Centre

V. L. Day, International Agency for Research on Cancer

A. Preussmann, German Cancer Research Centre

D. Schmähl, German Cancer Research Centre

S. Sanner, International Agency for Research on Cancer

S. Wagner, German Cancer Research Centre